Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ICOS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ICOS ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View ICOS Products |
| Gene Delivery | ICOS Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based functional assays. |
View ICOS Products |
| Benchmark Ab | Anti-ICOS (Sequence of Feladilimab / Vopratelimab) Recombinant positive control for binding and functional assays. |
View ICOS Products |
| Validator | ICOS siRNA Set For knockdown verification in primary T cells or cell lines. |
View ICOS Products |
| Related Target A | ICOSL (CD275) Natural ligand for ligand-blocking assays and receptor-ligand interaction studies. |
View ICOSL Products |
| Related Target B | PD-1 (CD279) Synergistic immune checkpoint. Often co-targeted in bispecific or combination therapies. |
View PD-1 Products |
| Related Target C | CTLA-4 (CD152) Homologous co-stimulatory pathway member used for selectivity and off-target screening. |
View CTLA-4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species Cross-Reactivity (Human vs. Cyno/Mouse) | Human, Cynomolgus, and Mouse ICOS recombinant proteins available with >95% purity verified by SDS-PAGE. |
| B7/CD28 Family Off-Target Screening | Homolog panel proteins (CD28, CTLA-4, PD-1) strictly verified by mass spectrometry and sequence analysis. |
| Lack of Reliable Reference Controls | Clinical Benchmark Antibodies (Biosimilars) synthesized using published sequences (Feladilimab, Vopratelimab). |
| Conformational Integrity in Cell-Based Assays | Lentiviral particles for stable cell line generation to preserve native conformation. |
Live ICOS/CD278 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of ICOS (Inducible T-cell COStimulator, CD278) represents a highly dynamic area of immunotherapy. As a key member of the CD28 superfamily, ICOS provides critical co-stimulatory signals for T-cell activation, proliferation, and survival. The global drug discovery landscape is bifurcated into two distinct strategic directions: oncology (utilizing agonist antibodies to stimulate anti-tumor T-cell responses) and autoimmune diseases (utilizing antagonist antibodies or ligand traps to suppress aberrant T-cell activation).
The race for ICOS therapeutics is intensifying, with major players shifting focus from traditional monospecific mAbs to bispecific antibodies and combination regimens. While early clinical setbacks with first-generation agonists highlighted the complexity of ICOS signaling and receptor internalization, the next wave of R&D is targeting precise epitope selection, Fc-engineering for optimal FcγR cross-linking, and bispecific constructs (e.g., PD-1/ICOS or CTLA-4/ICOS) to localize co-stimulation to the tumor microenvironment.
Competitive Modality & Indication Snapshot
Connecting market trends to assay needs is essential for developing competitive therapeutics. Below is an overview of ongoing industry modalities, key sponsors, and their corresponding assay requirements.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist Monoclonal Antibodies | GSK (Feladilimab), Jounce Therapeutics/Gilead (Vopratelimab) | Solid Tumors (Head & Neck, NSCLC) | Epitope mapping and receptor occupancy assays (Need high-purity ICOS ECD-Fc). |
| Antagonist / Ligand Traps | Alpine Immune Sciences (Acazicolcept / ALPN-101), Amgen (AMG 557) | Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome | Ligand-blocking assays (Need highly stable ICOSL recombinant proteins). |
| Bispecific Antibodies | Xencor, Macrogenics | Advanced Malignancies, Autoimmunity | Simultaneous binding kinetics and selectivity panels (Need homologous CD28/CTLA-4 proteins). |